Introduction
Type II collagen-induced arthritis (CIA) is a disease influenced by MHC class II haplotypes as well as non-MHC genes (1) (2) (3) (4) (5) . Mice bearing the H-2? haplotype on the DBA/1 background are highly susceptible. The importance of the MHC for CIA was clearly demonstrated by an elegant study of Brunsberg et al. (6) . I-A q molecules (associated with susceptibility) differ from I-A p molecules (associated with resistance) by only four amino acids in the I-Ap chain. Immunization of transgenic mice expressing a modified Ap p molecule, where the relevant positions were exchanged to resemble Ap q , with type II collagen (Cll) results in an enhanced autoimmune response and in the development of arthritis. Thus, MHC class II polymorphism can exert a dominant influence on the susceptibility to CIA. However, the relative resistance of C57BL/6 (H-2 b ) and B10.Q (H-^) mice regarding the induction of arthritis by immunization with Cll in complete Freund's adjuvant (CFA) appears to be due to the influence of as yet unidentified non-MHC background genes (3, 4) .
Usually, mice are immunized with Cll emulsified with CFA, that contains killed mycobactena as adjuvant, to induce CIA.
We have recently reported that IL-12 can replace mycobacteria as adjuvant and promote a severe joint disease in DBA/ 1 mice immunized with CM in incomplete Freund's adjuvant (IFA) by enhancing the cellular and the humoral immune response to Cll (7) . Because mycobactena/mycobacterial products can activate macrophages to synthesize IL-12 (8, 9) , differences in the release of IL-12 or in the response to IL-12, and as a consequence a qualitatively different immune response, could explain the failure of certain strains of mice to develop arthritis following immunization with Cll in CFA. This was the rationale to test the influence of IL-12 on the Cllspecific immune response as well as on the development of arthritis in 'CIA-resistant' mouse strains. Our results show that injections of IL-12 into C57BL/6 (H-2 b ) or B10.Q (H-^) mice immunized with Cll in IFA promoted the generation of Cllspecific IFN-y-producing T cells. However, in contrast to DBA/ 1 mice, there was virtually no enhancing effect of IL-12 treatment on the synthesis of Cll-specific antibodies and the incidence of arthritis remained low. This indicates that the mere development of Cll-specific T h 1-type cells does not necessarily result in arthritis and that as yet undefined modifier genes from the C57BL background might be responsible for the relative CIA resistance by limiting the effects of IL-12 on the humoral immune response to Cll.
Methods

Mice
DBA/1 mice were originally obtained from Charles River (Sulzfeld, Germany), C57BL/6 mice from the Zentralinstitut fur Versuchstierforschung (Hannover, Germany) and B10.Q mice from Bommice (Bomholtgard, Denmark). Animals of these strains as well as (DBA/1 xC57BL/6)F 1 mice were bred at the local animal facility. Female and male mice were used in the experiments at 8-12 weeks of age.
Reagents and antibodies
Streptavidin-peroxidase was purchased from BoehringerMannheim (Mannheim, Germany). Aluminum hydroxide (2 mg/ml AI(OH) 3 ) was bought from Eurobio (Raunheim, Germany). The peroxidase substrate 2,2-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS), keyhole limpet hemacyanin (KLH) and chicken Cll were obtained from Sigma (Munich, Germany). Cll was dissolved in 0.01 N acetic acid at a concentration of 4 mg/ml. Before using Cll in the stimulation of spleen cells, it was denatured by heat (30 min, 60°C). IFA was obtained from Difco (Detroit, Ml). Purified recombinant murine rlL-12 (>95% pure IL-12, as assessed by SDS-PAGE; <5 endotoxin U/mg, as determined by the Limulus amebocyte assay) was prepared from supernatant of transfected CHO cells (10) . A pair of mAb recognizing different epitopes of IFN-y (mAb R46A2 and biotinylated mAb AN-18.17.24) was used to determine IFN-y by ELISA as described previously (11) .
Immunization of mice and determination of arthritis
The animals were intradermaily immunized (into both auriculae and one site on the back) with 100 \ig of chicken Cll emulsified with an equal volume of IFA. The total volume per mouse was 100 nl emulsion. Booster immunizations were performed i.p. with 100 ng Cll in PBS in a total volume of 200 \i\. Some groups of mice additionaJly received IL-12 (i.p., 200 (il each mouse) at various doses (dissolved in PBS containing 1% syngeneic normal mouse serum) for 5 days (starting 1 day before the Cll immunization). Control mice received 200 nl PBS + 1% normal mouse serum for 5 days instead. Beginning 2 weeks after the priming immunization, the animals were visually inspected at regular intervals for signs of arthritis. Mice were scored positive for CIA if erythema and swelling of at least one digit and/or paw was observed.
Cll-specific spleen cell activation
Spleens of mice immunized with Cll in IFA (± IL-12) were prepared at the end of the respective experiments. Single cell suspensions were generated by mincing spleens through sterile wire mesh. Whole spleen cell suspensions were stimulated at a density of 10 6 /ml in 48-well culture plates with 100 ng/ml of heat-denatured Cll. Activation supernatants were collected at several time points (24, 48, 72 and 96 h). IFN-y production was determined by specific ELISA as described (11) . Data for the 72 h supernatants are presented.
Determination of the humoral anti-CII response including IgG subclasses
Mice were bled 1 week after the first boost (day 28) and at the end of the experiments to test for the presence of antibodies recognizing native Cll by ELISA. Briefly, ELISA plates (Greiner, Nurtmgen, Germany) were coated overnight at 4°C with antigen (10 jig/ml of native Cll, 50 nl/well) in phosphate buffer (0.1 M Na 2 HPO 4 , pH 9.2). Non-specific binding sites were saturated by overnight incubation with PBS containing 2% skimmed milk powder. Thereafter, antisera were diluted in PBS + 0.1% Tween 20 in serial 5-fold dilutions and added for 45 min followed by a 45 min incubation with isotype-specific (lgG1, lgG2a, lgG2b) biotinylated anti-mouse antisera (The Binding Site, Heidelberg, Germany) or biotinylated sheep anti-mouse Ig antiserum (total Ig). In the next step, streptavidin-peroxidase (1:10,000) in PBS + 0.1% Tween 20 was added for 45 min. Finally, the substrate ABTS in substrate buffer (40 mM citric acid, pH 4.5, H 2 O 2 at 0.0075%) was added. ELISA plates were read at 414 nm after 20-60 min in a microplate reader (Asys Hightech, Zinnsser, Frankfurt, Germany). Between each step all plates were washed three times with PBS containing 0.1% Tween 20. From the OD values of serial 2-fold dilutions of a standard serum, a standard curve was derived to calculate the antibody content (in arbitrary U/ml) in the different individual sera using the Mikrowin software (4 log parameter analysis). The means + SD of Cll-specific antibodies for all animals of each experimental group are presented.
Results
777e influence of IL-12 treatment on the development of arthritis and the Cll-specific immune response in DBA/1 and C57BU 6 mice immunized with Cll in IFA
In order to find out whether IL-12 would be able to promote CIA in C57BL/6 mice, several groups of animals of this strain Male DBA/1 or C57BL/6 mice were intradermally primed with 100 jig Clll in IFA. All animals were boosted again by injecting 100 |ig of soluble CM i p. after 3, 6 and 9 weeks. Some groups of mice were additionally treated with IL-12 (day -1 to +3) at the indicated concentrations All mice were inspected for clinical signs of arthritis (erythema, swelling of digits or paws) ND, not done.
(five female and five male mice/group) were immunized with CM in IFA. In some groups, mice additionally received injections of IL-12 at three different doses (1000, 200 and 40 ng; daily). For reasons of comparison, two groups of DBA/1 mice were immunized with CM in IFA and the animals of one group received in addition an optimal dose of IL-12 (200 ng/ daily). As reported earlier (7) and observed again (Table 1A) , DBA/1 mice immunized with CM in IFA did not develop clinical signs of arthritis during a long period of observation (Table  1A , day 41 to 100: CIA incidence 0/11) even after repeated immunizations with CM [this reflects the low incidence (0-20%) of spontaneous arthritis by mice of the local colony]. Coinjection of IL-12 promoted the development of joint disease in DBA/1 mice. At day 41 the CIA incidence was three out of nine mice and increased to seven out of eight mice at day 70 and day 100 (Table 1A) . Most of the seven arthritic mice had developed a severe arthritis with massive swelling and deformity of at least one paw (not shown). In striking contrast, administration of IL-12 failed to promote CIA in C57BL/6 mice. In the group immunized with CM in IFA alone, two mice showed erythema and slight swelling of some paws at day 39 after the first immunization (Table 1B) . However, these clinical signs of disease disappeared at later time points and the animals were free of symptoms between day 61 and 130. Likewise, only a few animals (3/30) of the IL-12-treated groups expressed symptoms of arthritis at an early time point that were no longer observed at the end of the experiment (Table  1B) . Thus, in contrast to the results with DBA/1 mice, injection of IL-12 did not result in an up-regulation of the incidence of CIA in C57BL/6 mice.
We next characterized and compared the Cll-specific humoral and cellular immune response of DBA/1 and C57BL/6 mice. When immunized with CM in IFA alone, mice of both strains developed an intermediate Cll-specific total Ig response (Fig. 1A) . Injection of IL-12 resulted in an upregulation of the Cll-specific antibody response to high Ig levels in DBA/1 mice, whereas total Ig synthesis remained 
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DBA/1 C57BI76 Fig. 1 . The influence of IL-12 treatment on the Cll-specific antibody response of DBA/1 and C57BL/6 mice. DBA/1 (n = 9 and 11) and C57BL/6 (n = 10) mice were immunized with CM in IFA plus (dark bars)/minus (white bars) treatment with IL-12 at a daily dose of 200 ng/mouse All mice were bled at day 28 after the first immunization and the sera were tested for antigen-specific antibody isotypes (for details see Methods) Results are presented in arbitrary U/ml ± SD. A, total Ig; B, lgG1; C, lgG2a, D, lgG2b
unchanged in C57BL/6 mice. Intermediate levels of Cllspecific lgG1 were produced in both strains that were slightly up-regulated in IL-12-treated mice (Fig. 1B) . The most striking effect of IL-12 treatment was observed in DBA/1 mice where the relatively low lgG2a and lgG2b synthesis, observed in the absence of IL-12, was up-regulated to high or intermediate levels respectively (Fig. 1C and D) . In contrast, a similar treatment of C57BL/6 mice slightly reduced (although statistically not significant) the Cll-specific lgG2a and lgG2b response which was, however, higher (intermediate levels, as compared with low levels in DBA/1 mice) in Cll-immunized C57BL/6 than in DBA/1 mice in the absence of IL-12 treatment (Fig. 1C and  D) . Taken together, these data demonstrate that administration of IL-12 has qualitatively opposite effects on the synthesis of Cll-specific lgG2a and lgG2b production in DBA/1 and C57BL/6 mice immunized with CM in IFA. Interestingly, the effect of IL-12 on the development of IFNy-producing T cells was comparable in both strains (Fig. 2) . Spleen cells of DBA/1 and C57BL/6 mice, immunized with CM in IFA ± IL-12 treatment, were prepared at the end of the arthritis experiments (DBA/1: day 100; C57BL/6: day 130) . Cll-specific lgG2a and lgG2b production in the sera was determined by IgG subclass-specific ELISA Results (mean ± SD) are expressed in arbitrary U/ml Table 2 . Time-course of CIA in Cll-immunized Fj mice (DBA/ 1 x C57BL/6) ± IL-12 treatment and single cell suspensions cultured in vitro in the absence or presence of Cll. IFN-Y synthesis was low in the absence of Cll. Addition of Cll to spleen cell cultures of either DBA/1 or C57BL/6 mice that had been immunized with Cll in IFA alone induced some IFN-y production. About 10-fold higher levels of IFN-y were detected in the supernatants of spleen cell cultures of both DBA/1 ( Fig. 2A ) and C57BL/6 (Fig. 2B ) mice immunized before with Cll in IFA and simultaneously injected with IL-12. Thus, administration of IL-12 promoted the generation of IFN-y-producing, Cll-specific T cells in both strains equally well.
Injection of IL-12 promotes arthritis and up-regulates Cllspecific lgG2a and lgG2b production in (DBA/1xC57BL/6)F 1 mice immunized with Cll in IFA
In order to find out whether the relative resistance of C57BL7 6 mice or the susceptibility of DBA/1 mice to CIA promoted by IL-12 is dominant, (DBA/1 xC57BL/6)F 1 mice were immunized with Cll in IFA and either left untreated or treated with three different doses of IL-12 ( Table 2) . Injections of IL-12 at all doses accelerated the onset of arthritis (Table 2 , day 55) and increased the incidence of CIA as compared with the group that did not receive IL-12. In particular, at a daily dose of 200 ng IL-12 promoted a very severe form of joint disease with high incidence ( (DBA/1 x C57BL/6) F, mice (female and male) received a priming immunization of 100 |ig CM in IFA mtradermally. All mice were boosted again by i p injections of 100 ng Cll in PBS 3, 6 and 9 weeks later Some groups of mice were additionally treated with IL-12 (day -1 to +3) at the indicated concentrations. The animals were monitored visually for arthritis (erythema, swelling of digits or paws). levels in (DBA/1 xC57BL/6)F 1 mice (Fig. 3) . Administration of IL-12 also resulted in enhanced IFN-y synthesis by spleen cells stimulated ex vivo with antigen (data not shown). Thus, regarding the effect of IL-12 on the synthesis of lgG2a and lgG2b antibodies as well as on the course of joint disease, (DBA/1 xCblQLIQ)?^ mice resemble DBA/1 mice and are highly susceptible to CIA. None of the animals of any of the groups developed erythema or swelling during the whole observation period (day 21 to 118). Similar to C57BL/6 mice but in contrast to DBA/1 mice, injections of IL-12 (200 ng/day) into Cll-immunized B10.Q mice slightly down-regulated the serum levels of Cll-specific lgG2a and lgG2b antibodies (Fig. 4) . However, as observed in all strains of mice immunized with Cll in IFA so far, administration of IL-12 resulted in enhanced (5.4-fold higher) IFN-Y synthesis by splenocytes activated ex vivo with Cll as compared with splenocytes from mice not treated with IL-12 ( Fig. 5) . Taken together, the results described so far indicate that the genetic background of C57BL/10 and C57BL/6 mice is probably responsible for the failure of IL-12 to enhance the humoral anti-CII response and to promote arthritis in these strains of mice despite the development of a strong T h 1-type response at the level of T cells.
Administration of IL-12 to C57BL/6 mice immunized with KLH adsorbed to aluminum hydroxide profoundly enhances the KLH-specific lgG2a and lgG2b response
The results obtained with Cll-immunized C57BL/6 and B10.Q mice raised the question of whether injection of IL-12 can generally not enhance antigen-specific lgG2a/2b responses in these strains of mice. We have recently reported that IL-12 can strongly up-regulate KLH-specific antibody responses in CBA/J mice (12) . Thus, we immunized C57BL/6 mice i.p. with KLH adsorbed to aluminum hydroxide. The developing humoral immune response was characterized by high levels of lgG1 (not shown), intermediate levels of lgG2b and very low levels of lgG2a (Fig. 6) . Treatment of KLH-immunized iooooo
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Fig. 6 . Treatment with IL-12 profoundly up-regulates the KLH-specific lgG2a and lgG2b synthesis in C57BL/6 mice immunized with KLH adsorbed to aluminum hydroxide C57BL/6 mice (n = 5/each group) were i.p. immunized with KLH (100 ng/each mouse) adsorbed (2 h at room temperature) to aluminum hydroxide ± IL-12 treatment (200 ng/day, each mouse). This procedure was repeated after 2 weeks. After 3 weeks all mice were bled and KLH-specific lgG2a and lgG2b production in the sera was determined by IgG subclass-specific ELISA. Results (mean ± SD) are shown in arbitrary U/ml (without IL-12, white bars; with IL-12, black bars).
C57BL/6 mice with IL-12 caused a strong enhancement of serum levels of lgG2a (400-fold) and lgG2b (40-fold). This demonstrates that the effects of IL-12 treatment on humoral immune responses in C57BL/6 mice are dependent on the antigen studied. In the case of KLH, IL-12 is a very potent adjuvant for KLH-specific lgG2a and lgG2b synthesis, whereas it fails to do so with Cll as antigen ( Fig. 1C and D) . The differential effect of IL-12 on the KLH-or Cll-specific antibody response of C57BL/6 mice is indeed due to the antigen and not a consequence of the mode of immunization, since injections of IL-12 up-regulated the KLH-specific lgG2a synthesis of C57BL/6 mice immunized id. with KLH in \FA about 100-fold, whereas IL-12 did not augment the Cllspecific antibody response of C57BL/6 mice immunized i.p. with Cll adsorbed to aluminum hydroxide (unpublished observations).
Discussion
In murine CIA, an animal model for human rheumatoid arthritis (13) , disease susceptibility is linked to the H-2 q haplotype expressed on the DBA/1 background (1-4). When immunized under the appropriate conditions (Cll in CFA or Cll in IFA + IL-12), DBA/1 mice mount a strong cellular and humoral antiCll immune response and develop a destructive arthritis in peripheral joints. Mice bearing the H-2 b or H-2 d haplotypes respond to Cll in CFA, yet do not (or only with low frequency) develop arthritis (1, 3, 4) . The purpose of this study was to test whether IL-12 would be able to up-regulate the Cll-specific immune response and to promote arthritis in 'CIA-resistant' mouse strains immunized with Cll in IFA. The Cll-specific antibody response of C57BL/6 and DBA/1 mice immunized with Cll in IFA is similar in magnitude and IgG subclass distribution. Simultaneous IL-12 treatment supported the generation of Cll-specific T h 1 cells equally well in both strains. However, injections of IL-12 strongly up-regulated Cll-specific antibody (lgG2a, lgG2b) synthesis and caused arthritis only in DBA/1 but not in C57BL/6 mice. Likewise, IL-12 treatment did neither enhance the Cll-specific antibody response nor trigger arthritis in C57BL/10 mice (data not shown). It appears to be the non-MHC background rather than the MHC haplotype that is responsible for this behaviour. Immunization of congenic C57BL/10.Q (H-2") mice with CI I/I FA ± IL-12 treatment again revealed that IL-12 failed to augment Cllspecific lgG2a production and to promote arthritis. Since B10.Q mice bear the same MHC as DBA/1 mice, this indicates that as yet unidentified non-MHC background genes modify the effect of IL-12 on antibody synthesis in vivo. Those of the DBA/1 background appear to be dominant because administration of IL-12 to (DBA/1 xC57BL/6)F 1 mice immunized with CII/IFA augmented IgG synthesis and induced arthritis with relatively high incidence. IL-12 is considered to be a cytokine promoting cellular immunity (14) and is a key mediator in the induction of Th1-type responses (11, 15, 16) . It also appears to be critically involved in the pathogenesis of several organ-specific autoimmune diseases (17) . Cellular immunity is frequently associated with T cell responsiveness and low or absent antibody synthesis (18) (19) (20) . The initial reports about the influence of IL-12 on Ig synthesis described mainly inhibitory effects (21) (22) (23) . In contrast, we recently reported that IL-12 can upregulate the synthesis of all IgG subclasses in CBA/J mice immunized with protein antigens adsorbed to aluminum hydroxide (12) . The effect was most pronounced for antigenspecific lgG2a which was up-regulated 100-to 1000-fold. Likewise, the KLH-specific lgG2a response of C57BL/6 (Fig.  6 ) mice was up-regulated 100-to 1000-fold after two immunizations with KLH and simultaneous IL-12 treatment. Moreover, Jelinek and Braaten (24) showed that IL-12 can support IgG synthesis by purified human B cells stimulated in vitro with Staphyloccocus aureus Cowan. Thus, IL-12 can enhance Ig synthesis by direct and indirect effects. In the context with CIA, it is intriguing that arthritis is only observed under those conditions where IL-12 exerted profound effects on the synthesis of the complement-fixing lgG2a and lgG2b antibody subclasses. This reflects the importance of the humoral antiCll response (1,2,7) and the synergy between Cll-specific antibodies and Cll-specific T cells (25, 26) in the pathogenesis of CIA. In C57BL/6 or B10.Q mice, where IL-12 failed to promote CIA, IL-12 did not exert any stimulatory effect on the synthesis of Cll-specific lgG2a and lgG2b after two (see Figs 1C, 1D and 4 (27, 28) . Whatever the mechanism is, the fact that the presence of Cll-specific Th1-type cells in combination with an intermediate Cll-specific antibody response with relatively high levels of lgG1 does not (or only with low incidence) lead to joint disease in IL-12-treated C57BL/6 or B10.Q mice indicates a functional heterogeneity within T h 1-type autoimmune responses. Thus, precisely defining the immunological conditions under which IL-12 augments antibody synthesis might be useful for the understanding of the pathogenesis of CIA and probably other autoimmune diseases.
In conclusion, our results show that IL-12 induces arthritis only in DBA/1 but not in C57BL/6 or B10.Q mice immunized with Cll in IFA, although it promotes the development of T cells producing IFN-y in all three strains. It is the intermediate Cll-specific antibody response of C57BL/6 or B10.Q mice that is not up-regulated by IL-12, due to the influence of so far unidentified non-MHC background genes, that correlates with resistance to CIA.
